ArticleJournal of the Egyptian National Cancer Institute2026
The additive value of 3D automated breast ultrasound and contrast enhanced spectral mammography in the assessment of suspicious breast lesions.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWorldwide, breast cancer is the most commonly diagnosed cancer among women accounting for over a million cases each year. Mammography still remains the gold standard for early detection of breast cancer. Contrast Enhanced Spectral Mammography (CESM) allows better estimation of the lesion size and detection of multifocal breast cancers. Automated breast ultrasound (ABUS) is an innovation of breast ultrasound that attains 3-D images of the entire breast overcoming the limitations of hand-held ultrasound. The aim is to evaluate the impact of 3D ABUS in correlation with CESM on the characterization and assessment of disease extent. DESIGN & POPULATION: The study was performed at the Female Imaging Unit of the National Cancer Institute (NCI), Cairo University and in Baheya Foundation. One hundred and six patients were randomly chosen out of patients who were initially given BIRADS IV - V by standard mammography. The contrast enhanced digital mammography and 3D automated ultrasound data were evaluated by two experienced radiologists; both observers were blinded to the pathological data of each patient.
resultsRegarding primary outcome of our study in assessment of tumor size, extension and multiplicity, the use of ABUS after CESM showed significant increase in the sensitivity of the test (80% for combined test versus 40% for CESM alone), while it showed almost no significant difference in specificity (70% for CESM and Combined tests).The ABUS also showed more accuracy in detection of suspicious lesions (61%) than the CESM (40%.)
conclusionABUS is considered a revolution in breast scanning by ultrasound imaging that can be used as a non-invasive complementary tool to CESM in assessment of suspicious breast lesions showing increased accuracy of study and patient outcome upon combing both of them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.